SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
K Mardinian, JJ Adashek, GP Botta, S Kato… - Molecular cancer …, 2021 - AACR
The SWI/SNF chromatin remodeling complex, via nucleosome topology modulation,
regulates transcription. The SMARCA4 (BRG1) subunit codes for the ATPase energy engine …
regulates transcription. The SMARCA4 (BRG1) subunit codes for the ATPase energy engine …
Updated prognostic factors in localized NSCLC
Simple Summary In resected lung cancer, adjuvant and neoadjuvant chemotherapy
following surgery are currently mainly based on TNM classification. With the validation and …
following surgery are currently mainly based on TNM classification. With the validation and …
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
MV Negrao, HA Araujo, G Lamberti, AJ Cooper… - Cancer discovery, 2023 - AACR
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRAS G12C-
mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 …
mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 …
[HTML][HTML] Genomic mapping of metastatic organotropism in lung adenocarcinoma
Summary We analyzed 2,532 lung adenocarcinomas (LUAD) to identify the
clinicopathological and genomic features associated with metastasis, metastatic burden …
clinicopathological and genomic features associated with metastasis, metastatic burden …
[HTML][HTML] Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
J Cantley, X Ye, E Rousseau, T Januario… - Nature …, 2022 - nature.com
Abstract The mammalian SWItch/Sucrose Non-Fermentable (SWI/SNF) helicase SMARCA4
is frequently mutated in cancer and inactivation results in a cellular dependence on its …
is frequently mutated in cancer and inactivation results in a cellular dependence on its …
Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung
SMARCA4/BRG1 encodes for one of two mutually exclusive ATPases present in mammalian
SWI/SNF chromatin remodeling complexes and is frequently mutated in human lung …
SWI/SNF chromatin remodeling complexes and is frequently mutated in human lung …
[HTML][HTML] SMARCA4: Current status and future perspectives in non-small-cell lung cancer
Y Tian, L Xu, X Li, H Li, M Zhao - Cancer Letters, 2023 - Elsevier
SMARCA4, also known as transcription activator, is an ATP-dependent catalytic subunit of
SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that …
SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that …
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
A Andrades, P Peinado, JC Alvarez-Perez… - Molecular cancer, 2023 - Springer
Hematological malignancies are a highly heterogeneous group of diseases with varied
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
[HTML][HTML] SMARCA4 and other SWItch/sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune …
Abstract Introduction The SWItch/Sucrose Nonfermentable (SWI/SNF) chromatin remodeling
complex acts as a regulatory component of transcription, and inactivating mutations (muts) …
complex acts as a regulatory component of transcription, and inactivating mutations (muts) …